Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy

Leelawat, Kawin; Sakchinabut, Sompong; Narong, Siriluck; Wannaprasert, Jerasak

doi:10.1186/1471-230x-9-30

Cited by 61 publications

(45 citation statements)

References 28 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1. All four assays are capable of reliable measurements below the cut-off values established for healthy individuals and reported in literature: CA125 35U/mL (12), HE4 40–85pM (age-dependent) (39), CA72-4 8.5U/mL (40) and MMP-7 7.4ng/mL (41). Reliable measurements of biomarker concentrations below cut-off levels are essential for establishing baselines for longitudinal biomarker monitoring.…”

Section: Resultsmentioning

confidence: 80%

A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care

Shadfan

Simmons

et al. 2015

Cancer Prevention Research

View full text Add to dashboard Cite

Point-of-care (POC) diagnostic platforms have the potential to enable low-cost, large-scale screening. As no single biomarker is shed by all ovarian cancers, multiplexed biomarker panels promise improved sensitivity and specificity to address the unmet need for early detection of ovarian cancer. We have configured the programmable bio-nano-chip (p-BNC) - a multiplexable, microfluidic, modular platform - to quantify a novel multimarker panel comprising CA125, HE4, MMP-7 and CA72-4. The p-BNC is a bead-based immunoanalyzer system with a credit-card-sized footprint that integrates automated sample metering, bubble and debris removal, reagent storage and waste disposal, permitting POC analysis. Multiplexed p-BNC immunoassays demonstrated high specificity, low cross-reactivity, low limits of detection suitable for early detection, and a short analysis time of 43 minutes. Day-to-day variability, a critical factor for longitudinally monitoring biomarkers, ranged between 5.4–10.5%, well below the biological variation for all four markers. Biomarker concentrations for 31 late-stage sera correlated well (R2 = 0.71 to 0.93 for various biomarkers) with values obtained on the Luminex® platform. In a 31 patient cohort encompassing early- and late-stage ovarian cancers along with benign and healthy controls, the multiplexed p-BNC panel was able to distinguish cases from controls with 68.7% sensitivity at 80% specificity. Utility for longitudinal biomarker monitoring was demonstrated with pre-diagnostic sera from 2 cases and 4 controls. Taken together, the p-BNC shows strong promise as a diagnostic tool for large-scale screening that takes advantage of faster results and lower costs while leveraging possible improvement in sensitivity and specificity from biomarker panels.

show abstract

Section: Resultsmentioning

confidence: 80%

A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care

Shadfan

Simmons

et al. 2015

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

“…11,12 Other markers may have clinical significance. Serum levels of matrix metalloproteinase-7 13 and tumour M2-PK 14 have been shown to have the potential to differentiate CCA from benign biliary tract disease with more sensitivity and specificity than CA19-9. In addition, an animal trial reported that a novel CCA-associated carbohydrate antigen may have potential as a marker for the early diagnosis of CCA.…”

Section: Diagnosismentioning

confidence: 99%

A review of the clinical diagnosis and therapy of cholangiocarcinoma

2013

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is the second most common primary hepatic malignancy worldwide. The incidence of intrahepatic CCA is increasing, whereas that of extrahepatic CCA is decreasing. This review looks at the new advances that have been made in the management of CCA, based on a PubMed and Science Citation Index search of results from randomized controlled trials, reviews, and cohort, prospective and retrospective studies. Aggressive interventional approaches and new histopathological techniques have been developed to make a histological diagnosis in patients with high risk factors or suspected CCA. Resectability of the tumour can now be assessed using multiple radiological imaging studies; the main prognostic factor after surgery is a histologically negative resection margin. Biliary drainage and/or portal vein embolization may be performed before extended radical resection, or liver transplantation may be undertaken in combination with neoadjuvant chemotherapy or chemoradiotherapy. Though many advances have been made in the management of CCA, the standard modality of treatment has not yet been established. This review focuses on the clinical options for different stages of CCA.

show abstract

“…Leelawat, Sakchinabut, Narog, and Wannaprasert analyzing the CEA, CA 19.9, MMP-7 and MMP-9 serum levels in patients with cholangiocarcinoma detected that only MMP-7 level was considerably higher in patients with cancer (25). Levels of total MMP-7 can be measured in human serum and it is feasible using a simple ELISA technique, as this has been recently shown in few other studies.…”

Section: Discussionmentioning

confidence: 99%

Serum Matrix Metalloproteinase-2, -7 and -9 (MMP-2, MMP-7, MMP-9) levels as Prognostic Markers in Patients with Colorectal Cancer

Kostova

Miceska

Labacevski

et al. 2012

JHSCI

View full text Add to dashboard Cite

Introduction: Matrix metalloproteinases are produced by tumour cells, hence, they may be associated with tumour progression including invasion, migration, angiogenesis and metastasis. Finding prognostic markers to better identify patients with higher risk for poor survival would be valuable in order to customize pre-and postoperative treatment as well as to enable closer follow-up of these patients. Aim of our study was to examine MMP-2, MMP-7 and MMP-9 serum levels and correlated them with pathological data such as stage of the colorectal cancer (CRC) and outcome. Methods: The investigation included 82 patients with operable CRC without distant metastases, who had underwent blood tests in order to determine the MMP-2, MMP-7 and MMP-9 serum levels in the following time periods: preoperatively, 3, 6, 9 and 12 months postoperatively. Results:The values of the investigated MMPs decrease postoperatively and start to increase 6 month later in patients of all stages of the disease, reaching the highest value 12 month postoperatively with statistically important differences of MMP-2, MMP-7 and MMP-7 serum levels in terms of disease staging and defi ned points of time. Analysis of the results showed that the MMP-2 serum levels obtained 3 and 12 months postoperatively, than MMP-7 serum levels 12 months postoperatively and the MMP-9 serum levels in all analyzed points in time were in signifi cant association with the CRC patients'outcome. Conclusion: The MMP-2, MMP-7 and especially MMP-9 serum values could be important indicators for diagnosis of the patients with CRC and for monitoring of disease progression.

show abstract

Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy

Cited by 61 publications

References 28 publications

A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care

A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care

A review of the clinical diagnosis and therapy of cholangiocarcinoma

Serum Matrix Metalloproteinase-2, -7 and -9 (MMP-2, MMP-7, MMP-9) levels as Prognostic Markers in Patients with Colorectal Cancer

Contact Info

Product

Resources

About